epinastine hydrochloride
Commercial- Indications
- Allergic conjunctivitis
Company intelligence / Profile preview
Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd.
Guangzhou, Guangdong, Chinaocusun.cn ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Ocusun has developed proprietary treatments for ophthalmic conditions such as cataracts and glaucoma. The company recently introduced its first product, sodium bromfenac eye drops, which have been approved for the market in China. The company operates a large R&D facility and is led by experienced scientists with a focus on innovative drug development for vision health.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculesNutraceuticals
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd..